Publicacions (210) Publicacions de FERNANDO LÓPEZ-RÍOS MORENO

2024

  1. Concordance in the estimation of tumor percentage in non-small cell lung cancer using digital pathology

    Scientific Reports, Vol. 14, Núm. 1

  2. Developments in predictive biomarker testing and targeted therapy in advanced stage non-small cell lung cancer and their application across European countries

    The Lancet Regional Health - Europe, Vol. 38

  3. Efficient Identification of Patients With NTRK Fusions Using a Supervised Tumor-Agnostic Approach

    Archives of pathology & laboratory medicine, Vol. 148, Núm. 3, pp. 318-326

  4. Final Results from SAUL, a Single-arm International Study of Atezolizumab in Unselected Patients with Pretreated Locally Advanced/Metastatic Urinary Tract Carcinoma

    European Urology Focus

  5. NTRK gene fusion testing and management in lung cancer

    Cancer Treatment Reviews, Vol. 127

  6. Optimizing tissue stewardship in non-small cell lung cancer to support molecular characterization and treatment selection: statement from a working group of thoracic pathologists

    Histopathology, Vol. 84, Núm. 3, pp. 429-439

  7. Programmed Death Ligand-1 and Tumor Mutation Burden Testing of Patients With Lung Cancer for Selection of Immune Checkpoint Inhibitor Therapies

    Archives of Pathology and Laboratory Medicine, Vol. 148, Núm. 7, pp. 757-774

  8. QIM24-189: Molecular Tumor Boards Excellence. Phase 1-State of the Art in Spain

    Journal of the National Comprehensive Cancer Network : JNCCN, Vol. 22, Núm. 25

  9. RET Fusion Testing in Patients With NSCLC: The RETING Study

    JTO Clinical and Research Reports, Vol. 5, Núm. 4

  10. Spatially Preserved Multi-Region Transcriptomic Subtyping and Biomarkers of Chemoimmunotherapy Outcome in Extensive-Stage Small Cell Lung Cancer

    Clinical Cancer Research, Vol. 30, Núm. 14, pp. 3036-3049

2023

  1. A narrative review of methods for the identification of ALK fusions in patients with non-small cell lung carcinoma

    Translational Lung Cancer Research, Vol. 12, Núm. 7, pp. 1549-1562

  2. Caracterización y clasificación molecular del cáncer de pulmón

    Revisiones en Cancer, Vol. 37, Núm. 3, pp. 114-120

  3. Clinical utility of checkpoint inhibitors against metastatic bladder cancer: overcoming challenges to find a way forward

    Expert Opinion on Biological Therapy, Vol. 23, Núm. 5, pp. 407-418

  4. Cost-Effectiveness of Next-Generation Sequencing Versus Single-Gene Testing for the Molecular Diagnosis of Patients With Metastatic Non-Small-Cell Lung Cancer From the Perspective of Spanish Reference Centers

    JCO Precision Oncology, Vol. 7

  5. New prognostic model in patients with advanced urothelial carcinoma treated with second-line immune checkpoint inhibitors

    Journal for immunotherapy of cancer, Vol. 11, Núm. 1

  6. Pan-TRK Immunohistochemistry to Optimize the Detection of NTRK Fusions: Removing the Hay When Looking for the Needle

    Modern Pathology

2022

  1. NSCLC Subtyping in Conventional Cytology: Results of the International Association for the Study of Lung Cancer Cytology Working Group Survey to Determine Specific Cytomorphologic Criteria for Adenocarcinoma and Squamous Cell Carcinoma

    Journal of Thoracic Oncology, Vol. 17, Núm. 6, pp. 793-805

  2. Predictive Biomarkers for Immunotherapy in Lung Cancer: Perspective From the International Association for the Study of Lung Cancer Pathology Committee

    Journal of Thoracic Oncology, Vol. 17, Núm. 12, pp. 1335-1354

  3. Rationale and design of ON-TRK: a novel prospective non-interventional study in patients with TRK fusion cancer treated with larotrectinib

    BMC Cancer, Vol. 22, Núm. 1

  4. Rethinking the role of biomarkers for operable non-small cell lung carcinoma: an effective collaboration with artificial intelligence algorithms

    Modern Pathology